Wednesday, November 12, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home European Markets

Is Nel ASA’s Hydrogen Strategy Gaining Critical Momentum?

Dieter Jaworski by Dieter Jaworski
November 12, 2025
in European Markets, Hydrogen, Renewable Energy, Turnaround
0
Nel ASA Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Recent developments at Norwegian hydrogen specialist Nel ASA suggest the company may be reaching an inflection point. This week’s announcement of a strategic collaboration with GreenH AS for two new hydrogen production facilities follows closely on the heels of what the company described as the largest order in its history, potentially signaling a shift in fortunes for the equity.

Quarterly Challenges Offset by Major Contracts

Despite the recent positive developments, Nel faced significant headwinds in its most recent quarterly report released in late October:

  • Contract Revenue Decline: Customer contract revenues fell by 17 percent
  • Order Intake Contraction: New orders plummeted 64 percent year-over-year
  • EBITDA Improvement: The loss narrowed to -37 million NOK, a substantial improvement from the previous year’s -90 million NOK

These lackluster figures highlight why the subsequent major contract wins are viewed as particularly timely. Market observers now speculate whether these substantial orders could drive a meaningful recovery in the company’s order book over the coming quarters as Nel works to convert its extensive sales pipeline into firm contracts.

Record-Breaking U.S. Order Fuels Market Optimism

The current wave of positive news began with a landmark announcement on November 5. Nel’s U.S. subsidiary secured a firm purchase order valued at $50 million from Kaupanes Hydrogen and HyFuel AS. This contract involves supplying 40 MW of containerized PEM electrolyzers, representing the largest PEM electrolyzer order in Nel’s corporate history.

Should investors sell immediately? Or is it worth buying Nel ASA?

  • Delivery Schedule: Commencing second half of 2026 through 2027
  • Operational Timeline: Projected to become operational by early 2028
  • Market Response: Equity value surged by approximately 20 percent following the announcement

The initial investor enthusiasm, however, proved somewhat transient. In recent trading on Tradegate, the shares experienced a slight pullback, declining 0.4 percent.

GreenH Collaboration Adds to Project Pipeline

The newly unveiled partnership with GreenH covers development at two Norwegian sites—Kristiansund and Slagentangen. Each facility is planned with a minimum capacity of 10 MW, adding at least 20 MW of combined capacity to Nel’s project portfolio. Both initiatives form part of Norway’s national strategy to establish a comprehensive domestic hydrogen value chain and are receiving financial support from the state-owned enterprise Enova.

“We are pleased to support GreenH in developing regional hydrogen infrastructure across Norway,” stated CEO Håkon Volldal. Final contractual details for the projects remain under negotiation.

The convergence of these substantial contracts suggests Nel ASA may be positioning itself for a potential operational turnaround, though market participants continue to monitor whether this positive momentum can be sustained amid the challenging financial results reported just weeks earlier.

Ad

Nel ASA Stock: Buy or Sell?! New Nel ASA Analysis from November 12 delivers the answer:

The latest Nel ASA figures speak for themselves: Urgent action needed for Nel ASA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 12.

Nel ASA: Buy or sell? Read more here...

Tags: Nel ASA
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

BioNTech Stock
Analysis

BioNTech Shares: A Turnaround Opportunity Emerges

November 12, 2025
Nestle Stock
Analysis

Nestlé Shares: A Test of Investor Patience

November 12, 2025
Opendoor Stock
AI & Quantum Computing

Opendoor’s Pivot: AI Ambition Meets Market Reality

November 12, 2025
Next Post
Gold Stock

Gold's Perfect Storm: Multiple Forces Converge

Applovin Stock

Applovin's AI Ambitions Fuel Record Growth Amid Market Concerns

Iqvia Stock

IQVIA Stock Surges on Strong Earnings and AI Focus

Recommended

Watsco Inc Delivers Impressive Financial Results for Fourth Quarter and FullYear 2023

2 years ago

Positive Restatement of ICU Eyewear Holdings Incs Financial Results for 2021 and 2022

2 years ago
Super Micro Computer Stock

All Eyes on Super Micro’s Earnings Release After Revenue Warning

1 week ago
Fluence Energy Stock

Fluence Energy Lands Transformative Contract for Europe’s Largest Battery Storage Facility

5 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Intellia Therapeutics Faces Mounting Pressure Following Clinical Trial Setback

Opendoor’s Pivot: AI Ambition Meets Market Reality

IonQ’s Quantum Ambition: A High-Stakes Balancing Act

PDS Biotechnology Faces Investor Backlash Over Equity Offering

Microsoft Leadership Sells Shares Following Stellar Quarterly Performance

IQVIA Stock Surges on Strong Earnings and AI Focus

Trending

BioNTech Stock
Analysis

BioNTech Shares: A Turnaround Opportunity Emerges

by Robert Sasse
November 12, 2025
0

After a prolonged period of disappointing its shareholders, the pioneering coronavirus vaccine developer is showing signs of...

Silber Preis Stock

Silver Nears Critical $51 Threshold as Rally Accelerates

November 12, 2025
Nestle Stock

Nestlé Shares: A Test of Investor Patience

November 12, 2025
Intellia Therapeutics Stock

Intellia Therapeutics Faces Mounting Pressure Following Clinical Trial Setback

November 12, 2025
Opendoor Stock

Opendoor’s Pivot: AI Ambition Meets Market Reality

November 12, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech Shares: A Turnaround Opportunity Emerges
  • Silver Nears Critical $51 Threshold as Rally Accelerates
  • Nestlé Shares: A Test of Investor Patience

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com